

Marcus Groettrup

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4992380/publications.pdf>

Version: 2024-02-01

153
papers

12,068
citations

19657

61
h-index

28297

105
g-index

155
all docs

155
docs citations

155
times ranked

10493
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. <i>Nature Medicine</i> , 2000, 6, 1348-1354.	30.7	674
2	A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. <i>Nature Medicine</i> , 2009, 15, 781-787.	30.7	533
3	Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. <i>Blood</i> , 2002, 100, 1354-1361.	1.4	451
4	Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity. <i>Cell</i> , 2012, 148, 727-738.	28.9	410
5	A role for the proteasome regulator PA28 $\hat{\pm}$ in antigen presentation. <i>Nature</i> , 1996, 381, 166-168.	27.8	350
6	A novel disulfide-linked heterodimer on pre $\hat{\epsilon}$ T cells consists of the T cell receptor $\hat{\iota}^2$ chain and a 33 kd glycoprotein. <i>Cell</i> , 1993, 75, 283-294.	28.9	320
7	Proteasomes in immune cells: more than peptide producers?. <i>Nature Reviews Immunology</i> , 2010, 10, 73-78.	22.7	292
8	Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands. <i>Cell</i> , 1996, 86, 253-262.	28.9	280
9	TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. <i>Vaccine</i> , 2008, 26, 1626-1637.	3.8	232
10	CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. <i>Blood</i> , 2004, 103, 1595-1601.	1.4	219
11	The immunoproteasome in antigen processing and other immunological functions. <i>Current Opinion in Immunology</i> , 2013, 25, 74-80.	5.5	214
12	The Interferon- $\hat{\iota}^3$ -inducible 11 S Regulator (PA28) and the LMP2/LMP7 Subunits Govern the Peptide Production by the 20 S Proteasome in Vitro. <i>Journal of Biological Chemistry</i> , 1995, 270, 23808-23815.	3.4	212
13	Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome. <i>Journal of Immunology</i> , 2010, 185, 634-641.	0.8	212
14	Prostaglandin E2 Is Generally Required for Human Dendritic Cell Migration and Exerts Its Effect via EP2 and EP4 Receptors. <i>Journal of Immunology</i> , 2006, 176, 966-973.	0.8	188
15	A Single Residue Exchange Within a Viral CTL Epitope Alters Proteasome-Mediated Degradation Resulting in Lack of Antigen Presentation. <i>Immunity</i> , 1996, 5, 115-124.	14.3	180
16	PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 475-482.	13.7	175
17	FAT10, a Ubiquitin-Independent Signal for Proteasomal Degradation. <i>Molecular and Cellular Biology</i> , 2005, 25, 3483-3491.	2.3	172
18	Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. <i>European Journal of Immunology</i> , 1999, 29, 4037-4042.	2.9	165

#	ARTICLE	IF	CITATIONS
19	Substantial reduction of naïve and regulatory T cells following traumatic stress. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 1117-1124.	4.1	159
20	Incorporation of major histocompatibility complex “ encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon- β . <i>European Journal of Immunology</i> , 1995, 25, 2605-2611.	2.9	157
21	Immunoproteasomes Largely Replace Constitutive Proteasomes During an Antiviral and Antibacterial Immune Response in the Liver. <i>Journal of Immunology</i> , 2001, 167, 6859-6868.	0.8	157
22	A third interferon- β induced subunit exchange in the 20S proteasome. <i>European Journal of Immunology</i> , 1996, 26, 863-869.	2.9	156
23	The Ubiquitin-like Protein FAT10 Forms Covalent Conjugates and Induces Apoptosis. <i>Journal of Biological Chemistry</i> , 2001, 276, 35334-35343.	3.4	144
24	Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. <i>EMBO Molecular Medicine</i> , 2014, 6, 226-238.	6.9	142
25	How an Inhibitor of the HIV-1 Protease Modulates Proteasome Activity. <i>Journal of Biological Chemistry</i> , 1999, 274, 35734-35740.	3.4	138
26	UBE1L2, a Novel E1 Enzyme Specific for Ubiquitin*. <i>Journal of Biological Chemistry</i> , 2007, 282, 23010-23014.	3.4	137
27	Interferon- β inducible exchanges of 20S proteasome active site subunits: Why?. <i>Biochimie</i> , 2001, 83, 367-372.	2.6	135
28	Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation. <i>Journal of Immunology</i> , 2012, 189, 4182-4193.	0.8	122
29	A cascading activity-based probe sequentially targets E1 “ E2 “ E3 ubiquitin enzymes. <i>Nature Chemical Biology</i> , 2016, 12, 523-530.	8.0	122
30	Opposite Fate of Endocytosed CCR7 and Its Ligands: Recycling versus Degradation. <i>Journal of Immunology</i> , 2006, 177, 2314-2323.	0.8	117
31	The unique functions of tissue-specific proteasomes. <i>Trends in Biochemical Sciences</i> , 2014, 39, 17-24.	7.5	111
32	Overexpression of the Proteasome Subunits LMP2, LMP7, and MECL-1, But Not PA28 β / β 2, Enhances the Presentation of an Immunodominant Lymphocytic Choriomeningitis Virus T Cell Epitope. <i>Journal of Immunology</i> , 2000, 165, 768-778.	0.8	110
33	A ubiquitin-like protein which is synergistically inducible by interferon- β and tumor necrosis factor- β . <i>European Journal of Immunology</i> , 1999, 29, 4030-4036.	2.9	109
34	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1524-1533.	4.2	104
35	Activating the ubiquitin family: UBA6 challenges the field. <i>Trends in Biochemical Sciences</i> , 2008, 33, 230-237.	7.5	101
36	The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection. <i>Journal of Immunology</i> , 2009, 183, 6145-6150.	0.8	100

#	ARTICLE	IF	CITATIONS
37	Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins. <i>Cell</i> , 2013, 152, 1184-1194.	28.9	99
38	An Altered T Cell Repertoire in MECL-1-Deficient Mice. <i>Journal of Immunology</i> , 2006, 176, 6665-6672.	0.8	93
39	Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. <i>Blood</i> , 2009, 113, 2451-2460.	1.4	93
40	Immunoproteasomes Down-Regulate Presentation of a Subdominant T Cell Epitope from Lymphocytic Choriomeningitis Virus. <i>Journal of Immunology</i> , 2004, 173, 3925-3934.	0.8	92
41	The Selective Proteasome Inhibitors Lactacystin and Epoxomicin Can Be Used to Either Up- or Down-Regulate Antigen Presentation at Nontoxic Doses. <i>Journal of Immunology</i> , 2000, 164, 6147-6157.	0.8	91
42	Cutting Edge: Neosynthesis Is Required for the Presentation of a T Cell Epitope from a Long-Lived Viral Protein. <i>Journal of Immunology</i> , 2001, 167, 4801-4804.	0.8	89
43	Evidence for the Existence of a Non-catalytic Modifier Site of Peptide Hydrolysis by the 20 S Proteasome. <i>Journal of Biological Chemistry</i> , 2000, 275, 22056-22063.	3.4	84
44	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 2935.	12.8	84
45	NEDD8 Ultimate Buster-1L Interacts with the Ubiquitin-like Protein FAT10 and Accelerates Its Degradation. <i>Journal of Biological Chemistry</i> , 2004, 279, 16503-16510.	3.4	82
46	Preferential positive selection of V β 2+CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V β a haplotypes: determination with a V β 2-specific monoclonal antibody. <i>European Journal of Immunology</i> , 1992, 22, 399-404.	2.9	79
47	USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. <i>Nature Communications</i> , 2010, 1, 13.	12.8	75
48	Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. <i>Journal of Immunological Methods</i> , 2004, 287, 109-124.	1.4	74
49	The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. <i>Biomaterials</i> , 2007, 28, 994-1004.	11.4	72
50	Long-lived Signal Peptide of Lymphocytic Choriomeningitis Virus Glycoprotein pGP-C. <i>Journal of Biological Chemistry</i> , 2003, 278, 41914-41920.	3.4	71
51	Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. <i>European Journal of Immunology</i> , 2010, 40, 3439-3449.	2.9	70
52	FAT10ylation as a signal for proteasomal degradation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 97-102.	4.1	70
53	A Cytomegalovirus Inhibitor of Gamma Interferon Signaling Controls Immunoproteasome Induction. <i>Journal of Virology</i> , 2004, 78, 1831-1842.	3.4	69
54	The immunoproteasome: a novel drug target for autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S74-9.	0.8	69

#	ARTICLE	IF	CITATIONS
55	Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. <i>Journal of Drug Targeting</i> , 2009, 17, 652-661.	4.4	68
56	The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. <i>Journal of Cell Science</i> , 2008, 121, 4079-4088.	2.0	67
57	The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. <i>Journal of Cell Science</i> , 2012, 125, 4576-85.	2.0	67
58	Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. <i>Journal of Controlled Release</i> , 2012, 162, 159-166.	9.9	66
59	FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. <i>Nature Communications</i> , 2012, 3, 749.	12.8	65
60	Cross-Presentation of the Long-Lived Lymphocytic Choriomeningitis Virus Nucleoprotein Does Not Require Neosynthesis and Is Enhanced via Heat Shock Proteins. <i>Journal of Immunology</i> , 2005, 175, 796-805.	0.8	64
61	Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. <i>FEBS Letters</i> , 2009, 583, 591-594.	2.8	63
62	Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon- γ -modulated proteasome subunits. <i>European Journal of Immunology</i> , 1997, 27, 1182-1187.	2.9	61
63	The ubiquitin-like modifier FAT10 in cancer development. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 79, 451-461.	2.8	61
64	Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. <i>Oncotarget</i> , 2017, 8, 50873-50888.	1.8	61
65	Expression and subcellular localization of mouse 20S proteasome activator complex PA28. <i>FEBS Letters</i> , 1997, 413, 27-34.	2.8	60
66	Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1106-1114.	3.3	60
67	The proteasome regulator PA28 β can enhance antigen presentation without affecting 20S proteasome subunit composition. <i>European Journal of Immunology</i> , 2000, 30, 3672-3679.	2.9	59
68	CD8 α^+ Dendritic Cells and Macrophages Cross-Present Poly(D,L-lactate-co-glycolate) Acid Microsphere-Encapsulated Antigen In Vivo. <i>Journal of Immunology</i> , 2011, 187, 2112-2121.	0.8	58
69	Pronounced up-regulation of the PA28 β proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. <i>European Journal of Immunology</i> , 2001, 31, 3271-3280.	2.9	57
70	Reduced Immunoproteasome Formation and Accumulation of Immunoproteasomal Precursors in the Brains of Lymphocytic Choriomeningitis Virus-Infected Mice. <i>Journal of Immunology</i> , 2010, 185, 5549-5560.	0.8	57
71	The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: Evidence from a randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2014, 54, 1-10.	3.1	57
72	The UBA Domains of NUB1L Are Required for Binding but Not for Accelerated Degradation of the Ubiquitin-like Modifier FAT10. <i>Journal of Biological Chemistry</i> , 2006, 281, 20045-20054.	3.4	56

#	ARTICLE	IF	CITATIONS
73	Subunit specific inhibitors of proteasomes and their potential for immunomodulation. <i>Current Opinion in Chemical Biology</i> , 2014, 23, 16-22.	6.1	56
74	T cell receptor \hat{I}^2 chain dimers on immature thymocytes from normal mice. <i>European Journal of Immunology</i> , 1993, 23, 1393-1396.	2.9	54
75	Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)â€”Mediated Anti-tumor Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 707.	4.8	53
76	Coâ€”inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. <i>EMBO Reports</i> , 2018, 19, .	4.5	51
77	The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells. <i>Nature Immunology</i> , 2015, 16, 950-960.	14.5	49
78	The ubiquitin-like modifier FAT10 decorates autophagy targeted <i>S<i>almonella</i></i> and contributes to resistance of mice. <i>Journal of Cell Science</i> , 2014, 127, 4883-93.	2.0	48
79	Inactivation of a Defined Active Site in the Mouse 20S Proteasome Complex Enhances Major Histocompatibility Complex Class I Antigen Presentation of a Murine Cytomegalovirus Protein. <i>Journal of Experimental Medicine</i> , 1998, 187, 1641-1646.	8.5	47
80	Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 140-149.	4.1	46
81	Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. <i>Journal of Cell Science</i> , 2008, 121, 2759-2767.	2.0	45
82	The Antiviral Immune Response in Mice Devoid of Immunoproteasome Activity. <i>Journal of Immunology</i> , 2011, 187, 5548-5557.	0.8	44
83	Stable Antigen Is Most Effective for Eliciting CD8⁺T-Cell Responses after DNA Vaccination and Infection with Recombinant Vaccinia Virus<i> In Vivo</i>. <i>Journal of Virology</i> , 2012, 86, 9782-9793.	3.4	43
84	Why the Structure but Not the Activity of the Immunoproteasome Subunit Low Molecular Mass Polypeptide 2 Rescues Antigen Presentation. <i>Journal of Immunology</i> , 2012, 189, 1868-1877.	0.8	43
85	Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renalâ€”transplantation. <i>Kidney International</i> , 2018, 93, 670-680.	5.2	43
86	Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis. <i>Frontiers in Immunology</i> , 2018, 9, 2386.	4.8	43
87	Selective proteasome inhibitors: modulators of antigen presentation?. <i>Drug Discovery Today</i> , 1999, 4, 63-71.	6.4	41
88	Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. <i>Journal of Controlled Release</i> , 2011, 151, 278-285.	9.9	41
89	Ubiquitylation of the chemokine receptor CCR7 enables efficient receptor recycling and cell migration. <i>Journal of Cell Science</i> , 2012, 125, 4463-74.	2.0	41
90	Prevention of neuronal apoptosis by astrocytes through thiol-mediated stress response modulation and accelerated recovery from proteotoxic stress. <i>Cell Death and Differentiation</i> , 2018, 25, 2101-2117.	11.2	39

#	ARTICLE	IF	CITATIONS
91	Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. <i>Molecular Immunology</i> , 2013, 53, 274-282.	2.2	37
92	Cross-Talk Between TCR and CCR7 Signaling Sets a Temporal Threshold for Enhanced T Lymphocyte Migration. <i>Journal of Immunology</i> , 2011, 187, 5645-5652.	0.8	36
93	The combination of TLR ϵ adjuvantation and electroporation ϵ mediated delivery enhances <i>in vivo</i> antitumor responses after vaccination with HPV ϵ 16 E7 encoding DNA. <i>International Journal of Cancer</i> , 2011, 128, 473-481.	5.1	35
94	Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV ϵ induced meningitis. <i>European Journal of Immunology</i> , 2016, 46, 104-113.	2.9	35
95	Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic <i>Candida albicans</i> infection in mice. <i>Scientific Reports</i> , 2016, 6, 19434.	3.3	34
96	No essential role for tripeptidyl peptidase ϵ ,II for the processing of LCMV-derived T cell epitopes. <i>European Journal of Immunology</i> , 2007, 37, 896-904.	2.9	31
97	Tumor eradication by immunotherapy with biodegradable PLGA microspheres ϵ an alternative to incomplete Freund's adjuvant. <i>International Journal of Cancer</i> , 2011, 129, 407-416.	5.1	31
98	Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. <i>Hepatology</i> , 2001, 33, 1282-1287.	7.3	30
99	Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome. <i>British Journal of Pharmacology</i> , 2018, 175, 38-52.	5.4	30
100	NUB1 modulation of GSK3 β reduces tau aggregation. <i>Human Molecular Genetics</i> , 2012, 21, 5254-5267.	2.9	29
101	Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF- κ B activation. <i>Molecular Immunology</i> , 2017, 83, 147-153.	2.2	29
102	The ubiquitin-like modifier FAT10 interferes with SUMO activation. <i>Nature Communications</i> , 2019, 10, 4452.	12.8	29
103	The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense. <i>Molecular Immunology</i> , 2015, 68, 129-132.	2.2	28
104	Investigations into the auto ϵ FAT ϵ 10ylation of the bispecific ϵ 2 conjugating enzyme ϵ UBA ϵ 6 ϵ specific ϵ 2 enzyme 1. <i>FEBS Journal</i> , 2014, 281, 1848-1859.	4.7	25
105	Conjugation of the Ubiquitin Activating Enzyme UBE1 with the Ubiquitin-Like Modifier FAT10 Targets It for Proteasomal Degradation. <i>PLoS ONE</i> , 2015, 10, e0120329.	2.5	25
106	The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation. <i>Nature Communications</i> , 2018, 9, 3321.	12.8	25
107	Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. <i>Kidney International</i> , 2019, 95, 611-623.	5.2	25
108	Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. <i>Genes and Immunity</i> , 2020, 21, 273-287.	4.1	25

#	ARTICLE	IF	CITATIONS
109	Analyzing structure–function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells. <i>Nucleic Acids Research</i> , 2016, 44, gkw859.	14.5	23
110	Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy. <i>Cell Reports</i> , 2021, 34, 108857.	6.4	22
111	On the Role of the Immunoproteasome in Protein Homeostasis. <i>Cells</i> , 2021, 10, 3216.	4.1	22
112	The Ubiquitin-like Modifier FAT10 Is Selectively Expressed in Medullary Thymic Epithelial Cells and Modifies T Cell Selection. <i>Journal of Immunology</i> , 2015, 195, 4106-4116.	0.8	20
113	The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1. <i>Journal of Biological Chemistry</i> , 2019, 294, 4315-4330.	3.4	20
114	The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire. <i>European Journal of Immunology</i> , 2018, 48, 419-429.	2.9	19
115	Immunoproteasome-Specific Inhibitors and Their Application. <i>Methods in Molecular Biology</i> , 2012, 832, 391-401.	0.9	18
116	Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion. <i>Journal of Immunology</i> , 2019, 203, 1776-1785.	0.8	18
117	The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader–derived T cell epitope. <i>Molecular Immunology</i> , 1998, 35, 581-591.	2.2	17
118	The Inherited Blindness Protein AIPL1 Regulates the Ubiquitin-Like FAT10 Pathway. <i>PLoS ONE</i> , 2012, 7, e30866.	2.5	17
119	Endosomal trafficking of open Major Histocompatibility Class I conformers—Implications for presentation of endocytosed antigens. <i>Molecular Immunology</i> , 2013, 55, 149-152.	2.2	17
120	Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease. <i>Journal of Controlled Release</i> , 2015, 216, 121-131.	9.9	17
121	Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 340-348.	4.1	15
122	No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes. <i>Immunogenetics</i> , 2015, 67, 51-60.	2.4	15
123	The STEAP1 _{262–270} peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice—A new approach to immunotherapy against prostate carcinoma. <i>Prostate</i> , 2016, 76, 456-468.	2.3	15
124	Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome. <i>ACS Central Science</i> , 2020, 6, 241-246.	11.3	15
125	An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma. <i>Molecular Therapy</i> , 2012, 20, 555-564.	8.2	14
126	On the role of the immunoproteasome in transplant rejection. <i>Immunogenetics</i> , 2019, 71, 263-271.	2.4	14

#	ARTICLE	IF	CITATIONS
127	The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28 $\hat{\pm}$ and equally degrade FAT10. <i>Molecular Immunology</i> , 2019, 113, 22-30.	2.2	14
128	The ubiquitin-like modifier FAT10 â€“ much more than a proteasome-targeting signal. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	14
129	The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. <i>Journal of Immunological Methods</i> , 2000, 237, 199-202.	1.4	13
130	Advances in Prostate Cancer Immunotherapies. <i>Drugs and Aging</i> , 2007, 24, 197-221.	2.7	13
131	A novel cytosolic class I antigenâ€processing pathway for endoplasmicâ€reticulumâ€targeted proteins. <i>EMBO Reports</i> , 2007, 8, 945-951.	4.5	13
132	Defective immuno- and thymoproteasome assembly causes severe immunodeficiency. <i>Scientific Reports</i> , 2018, 8, 5975.	3.3	13
133	The ubiquitin-like modifier FAT10 is required for normal IFN- $\hat{3}$ production by activated CD8+ T cells. <i>Molecular Immunology</i> , 2019, 108, 111-120.	2.2	13
134	Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation. <i>Molecular Immunology</i> , 2016, 69, 99-105.	2.2	12
135	Evidence for an involvement of the ubiquitinâ€like modifier ISG15 in MHC class I antigen presentation. <i>European Journal of Immunology</i> , 2021, 51, 138-150.	2.9	12
136	The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions. <i>Immunogenetics</i> , 2018, 70, 429-438.	2.4	11
137	Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. <i>Prostate</i> , 2005, 64, 323-331.	2.3	9
138	Analgesia in mice with experimental meningitis reduces pain without altering immune parameters. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2015, 32, 183-9.	1.5	9
139	Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10. <i>Methods in Enzymology</i> , 2019, 618, 229-256.	1.0	8
140	Regulation of Interferon Induction by the Ubiquitin-Like Modifier FAT10. <i>Biomolecules</i> , 2020, 10, 951.	4.0	7
141	Immunoproteasome Upregulation Is Not Required to Control Protein Homeostasis during Viral Infection. <i>Journal of Immunology</i> , 2021, 206, 1697-1708.	0.8	7
142	Detection and Analysis of FAT10 Modification. <i>Methods in Molecular Biology</i> , 2012, 832, 125-132.	0.9	7
143	Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome. <i>European Journal of Immunology</i> , 2022, 52, 1510-1522.	2.9	7
144	Newly translated proteins are substrates for ubiquitin, ISG15, and FAT10. <i>FEBS Letters</i> , 2017, 591, 186-195.	2.8	6

#	ARTICLE	IF	CITATIONS
145	No prolongation of skin allograft survival by immunoproteasome inhibition in mice. <i>Molecular Immunology</i> , 2017, 88, 32-37.	2.2	6
146	The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation. <i>Journal of Biological Chemistry</i> , 2020, 295, 14402-14418.	3.4	6
147	Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
148	PLGA particle vaccination elicits resident memory CD8 T cells protecting from tumors and infection. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 175, 106209.	4.0	5
149	Using Protease Inhibitors in Antigen Presentation Assays. <i>Methods in Molecular Biology</i> , 2013, 960, 31-39.	0.9	3
150	FAT10 localizes in dendritic cell aggresome-like induced structures and contributes to their disassembly. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	2
151	Silencing of the proteasome and oxidative stress impair endoplasmic reticulum targeting and signal cleavage of a prostate carcinoma antigen. <i>Biochemical and Biophysical Research Communications</i> , 2021, 554, 56-62.	2.1	1
152	A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection. <i>Journal of Visualized Experiments</i> , 2022, , .	0.3	1
153	Analysis and expression of a cloned pre-T cell receptor gene. <i>Science</i> . 1994. 266: 1208-1212. <i>Journal of Immunology</i> , 2009, 182, 5165-9.	0.8	1